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Highlights 
 A 3D-QSAR model was produced for the FABP4 inhibitors 
 A scaffold hopping suggested 3,000 potentially active FABP4 inhibitors 
 Three synthesized molecules have shown an IC50 between 3.70 and 5.59 M 
 
Keywords: FABP4 inhibitors, aP2, A-FABP, 3D-QSAR, scaffold-hopping, BMS309403 analogs, 
thiazole, triazole, Forge and Spark software. 
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Abstract 
Following on the recent publication of pharmacologically relevant effects, small molecule inhibitors 
of adipocyte fatty-acid binding protein 4 (FABP4) have attracted high interest. FABP4 is mainly 
expressed in macrophages and adipose tissue, where it regulates fatty acid storage and lipolysis, 
being also an important mediator of inflammation. In this regard, FABP4 recently demonstrated an 
interesting molecular target for the treatment of type 2 diabetes, other metabolic diseases and some 
type of cancers. In the past years, hundreds of effective FABP4 inhibitors have been synthesized. In 
this paper, a quantitative structure-activity relationship (QSAR) model has been produced, in order 
to predict the bioactivity of FABP4 inhibitors. The methodology has been combined with a 
scaffold-hopping approach, allowing to identify three new molecules that act as effective inhibitors 
of this protein. These molecules, synthesized and tested for their FABP4 inhibitor activity, showed 
IC50 values between 3.70 and 5.59 M, with a high level of agreement with the predicted values. 
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1. Introduction 
Fatty acids (FAs) are a class of carboxylic acids that carries out different vital functions in the 
organism [1]. Recently, it was proved that chronically elevated plasma fatty acids lead to specific 
physiological disorders [2]. For instance, FAs elevated levels are connected with type 2 diabetes 
[3], obesity [4] and atherosclerosis [5]. Due to the poor solubility in water of FAs, their trafficking 
requires a cluster of specific carrier proteins, such as albumin, lipocalins and fatty acid-binding 
proteins (FABPs), that facilitates their transport increasing their water solubility [6]. The adipocyte 
FABP (A-FABP, aP2 or FABP4) is highly expressed in adipocytes and it is regulated by 
peroxisome-proliferator-activated receptor-c agonists, as well as by the levels of insulin and fatty 
acids [7]. Studies in FABP4 knockout mice have shown that FABP4 has a key role in many aspects 
of the metabolic syndrome [8, 9], showing that the lack of this protein partially prevents the 
advancement of insulin resistance and obesity in mice. 
Therefore, pharmacological agents that inhibit FABP4 function can mimic the phenotype of 
FABP4-deficient mice and small molecules that inhibit FABP4 might be useful candidates for the 
treatment of metabolic syndromes. FABPs play also an important role in carcinogenesis [10]. 
Modified FABPs expression were described for prostate, bladder, renal cell carcinoma and other 
types of cancer cells [11-13], although FABPs biological function in cancer remains mostly unclear 
[14]. 
Recently, a variety of effective FABP4 inhibitors have been developed [15], but unfortunately, none 
of them is currently in the clinical research phases, and only BMS309403 (Figure 1) has been 
systematically studied in both in vitro and in vivo animal models [16-18]. In Table 1 are reported 
the different classes of FABP4 inhibitors [15], in Figure 1 and Table 2 some representative 
examples and their biological evaluations, respectively. 
 
Table 1 
Various chemical classes of FABP4 inhibitors. 
Chemical Classification Chemical Structure 
Pyrazole derivatives 
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Oxazole derivatives 
 
Imidazole derivatives 
 
Indole derivatives 
 
Benzimidazole derivatives 
 
Thiophene and thiazoles derivatives 
 
Pyrimidine, bicyclic pyridine and quinoxaline derivatives 
 
Urea and carbamoyl derivatives 
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Fig. 1. Structures of different FABP4 selective inhibitors. 
 
Table 2 
Experimental biological activity of FABP4 inhibitors. 
Compound IC50 or Ki (M)  Reference 
BMS309403 0.71a [19] 
HTS01037 0.67b [20] 
1 0.45
a [21] 
2 1.00
a [22] 
3 0.001
b [23] 
4 4.00
a [24] 
5 1.30
a [25] 
6 0.033
b [26] 
a Experimental IC50; 
b Experimental Ki 
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Computer-aided drug design shows a promising and effective tool for the identification of FABP4 
inhibitors. Indeed, different structure-based computational approaches have been already performed 
in the context of FABP4 research, for instance virtual screening studies have been reported with 
different libraries of compounds, leading to important biological results [27, 28]. In line with our 
recent interest in the development of QSAR models and related applications, in order to identify 
novel hit compounds, herein we report the development of a 3D-QSAR approach for FABP4 [29-
35]. Moreover, the 3D-QSAR model was combined with a scaffold-hopping analysis, allowing the 
design of new potent molecules able to interact with the binding site and inhibit the FABP4. The 
3D-QSAR model for the determination of FABP4 endpoints was developed using the software 
Forge, while Spark was adopted to produce a scaffold-hopping analysis and generate a virtual 
library of FABP4 inhibitors. This 3D-QSAR model was used to elucidate SAR data and predict 
FABP4 endpoints for new molecules. Three of the ligands suggested by the scaffold-hopping 
analysis were synthesized and tested in vitro yielding IC50 values between 3.70 and 5.59 M. 
 
2. Results and discussion 
2.1. Statistical analysis 
The regression method used in Forge was PLS (SIMPLS algorithm) [36-40]. As presented in the 
Data in Brief related article, two different alignment methods were initially tested (i.e., structure-
based and ligand-based). The predictive ability of the generated QSAR model was confirmed by 
several statistical tests. The cross-validation regression coefficient (q
2
) was calculated based on the 
PRESS (Prediction error sum of squares) and SSY (Sum of squares of deviation of the experimental 
values from their mean): 
      
     
   
    
                  
                  
 
Yexp = experimental activity of training set compound 
Ypred = predicted activity of training set compound 
Ymean = mean values of the activity of training set compound 
 
The statistical results of both models are reported in Table 3 and Figure 2. 
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Table 3 
3D-QSAR model statistics of the different alignment protocols. 
Alignment protocols Leave-one-out q
2
 Training set r
2
 
3D-QSAR Based on Docked Poses (structure based) 0.38 0.90 
3D-QSAR Based on Forge Alignments (ligand based) 0.64 0.92 
 
 
 
Fig. 2. 3D-QSAR model statistics: (up) 3D-QSAR based on docked poses (structure based); (down) 3D-QSAR based 
on Forge alignments (ligand based). 
 
As demonstrated above (Fig. 2, Table 3), the ligand-based approach results to be more reliable (r
2
 = 
0.92, q
2
 = 0.64) than the structure-based alignment, which has an increased noise (r
2
 = 0.90, q
2
 = 
0.38). At this point, the ligand-based 3D-QSAR align model was further validated with a set of 
external compounds (i.e. test set). Indeed, a more reliable estimation of robustness comes from 
separate training and test sets. Out of 120 molecules, we randomly choose 96 molecules (covering 
the whole range of activities of the compounds) as a training set to build the model, while the 
remaining 24 compounds served as a test set to evaluate the model. 
The statistical reliability of this model was also validated by the determination of the r
2
test, using 
the following equation: 
          
                       
                   
 
Ypredtest = predicted activity of test set compound by QSAR equation 
Ytest = experimental activity of test set compound 
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Ymean = mean values of the activity of training set compound 
The results are presented in Figures 3 and 4. The 11-components model shows both good predictive 
and descriptive capability as it is shown by the good r
2
 (0.99) and q
2
 (0.69) [41] values for the 
training and the cross-validated training sets. The plot of experimental vs. predicted activity for the 
compounds, in both the training set and the cross-validated training set (q
2
 = 0.69), shows a 
reasonable distribution of the values. The plot of experimental vs. predicted activity for the 
compounds in the test set is still reasonably good with only few outliers and a good cross-validated 
r
2
 of 0.73. 
 
Fig. 3. The 11-component 3D-QSAR model – Experimental vs. Predicted activity of the compounds in the training set. 
 
 
Fig. 4. The 11-component 3D-QSAR model – Experimental vs. Predicted activity of the compounds in the test set. 
 
The graphical interpretation of the model is shown in Figure 5, where the 3D-QSAR model results 
are superposed to the structure of the BMS309403. In this model representation, the larger the 
points are and the stronger is the correlation between the electrostatic/steric fields in that position. 
This 3D-QSAR model is clearly described by both steric and electrostatic effects and well describes 
the behavior of the different classes of FABP4 inhibitors inside the binding pocket of FABP4. To 
reveal the key features of the series under investigation, a structure-activity relationship (SAR) 
study was also performed through activity-atlas (AA) visualization software [42]. Figure 6 
illustrates the results of AA calculations, where the AA map is superimposed to BMS309403 lead 
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compound. The different colors on the map highlight electrostatic, hydrophobic and shape features. 
A more positive electrostatic field increases the receptor-affinity in the red area, whereas in the blue 
region a more negative electrostatic field increases the affinity. Green and violet areas represent the 
steric and bulk/hydrophobic interactions. A steric/bulk interaction improves the binding affinity in 
the green area. On the other hand, in the violet area, a steric/bulk interaction decreases the affinity. 
 
 
Fig. 5. Electrostatic and Steric coefficients for the FABP4 model superposed to the BMS309403. A) Steric coefficients. 
B) Electrostatic coefficients. C) Contributions to the predicted affinity for BMS309403. 
 
Fig. 6. The AA FABP4 model map is superimposed to the BMS309403. Molecular insight of SAR mechanism models, 
revealing the different lead optimization sites of active compounds. Red color shows positive field region controlling 
the activity and blue color the negative ones. Green color shows favorable shape/hydrophobic regions and purple color 
the unfavorable ones. 
 
2.2. Scaffold-hopping analysis 
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To design novel hit compounds with FABP4 inhibitory activity, by using the above-reported 
information from the QSAR model, we decided to use a bioisostere and fragment replacement 
software tool (i.e. Spark; Cresset group) and produce a scaffold hopping analysis to generate a 
virtual library of FABP4 ligands [43]. As reported in Figure 7, Different portions of the 
BMS309403 were studied in the bioisosteric replacement. Once the virtual library was created, the 
newly designed molecules were scored assuming that if their calculated/aligned fields are highly 
similar to that of the original compounds present in the 3D-QSAR model, the resulting biological 
activity would have been comparable [44, 45]. The bioisosteric replacement was performed through 
the same 178,558 fragments for each part, which derive from ChEMBL and Zinc databases [46, 47] 
(see the Data in Brief related article). Five hundred compounds were generated for each substitution 
producing 3,000 hits in total, which were then scored in the 3D-QSAR model. 
The first top-scoring compounds (best predicted pIC50 values) resulting from the bioisosteric 
replacement of series 1–6 are reported in Figure 8, while the full set of compounds are reported as 
SMILES in the Data in Brief related article. Overall, the results indicate that the bioisosteric 
replacement and the following 3D-QSAR model evaluation generate compounds with a suitable 
chemical structure for the inhibition of FABP4. 
 
 
Fig. 7. Bioisosteric replacement of the lead compound BMS309403. 
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Fig. 8. First top-scored compounds derived from series 1–6, with regards to FABP4 predicted pIC50. 
 
The results of the scaffold-hopping analysis were used for the design of a novel series of 
BMS309403-based derivatives. In particular, we focused our attention on the results of the series 3 
and 4. In series 3, the most potent compound was predicted as a thiazole derivate of the 
BMS309403, where the central pyrazole is substituted by a thiazole. In series 4, the most potent 
predicted compound was the term with a triazole as the aromatic linker, which can be easily 
introduced through a click chemistry reaction. Using these information, we designed the new series 
of compounds AST_1–3 (Fig. 9). The molecules were imported into Forge and aligned/evaluated 
with the 3D-QSAR model. Interestingly, AST_1–3 were predicted to have a pIC50 of 5.4, 5.9 and 
5.6, respectively, and demonstrated an IC50 of 3.98, 1.25 and 2.51 M. To prove the effective 
predicting capabilities of our model, we decide to set up a synthetic route that affords AST_1–3. 
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Fig. 9. Structures of AST_1–3. 
 
2.3. Synthesis 
The synthesis (Scheme 1) starts from commercially available aldehydes (i.e. benzaldehyde, 
naphthaldehyde, and 4-chloro benzaldehyde) and the Grignard reagent generated in situ by benzyl 
bromide and magnesium. The alcohol 10 was firstly oxidized with PCC (Pyridinium 
chlorochromate) to give compounds 11 and then monohalogenated, at the -position, with bromine 
under acidic conditions (compounds 12). The 2‐ aminobenzene‐ 1‐ carbothioamide 14 was 
generated from the respective amide 13 and the Lawesson’s reagent. Subsequently, the thioamide 
was reacted with intermediate 12 to give the thiazole derivatives 15. The butynoic acid 17 was 
obtained by oxidation of 3-butyn-1-ol 16. Lastly, the treatment of 15 with t-BuONO (tert-Butyl 
nitrite) and azidotrimethylsilane afforded the azide intermediate and the final analogs were 
assembled by using 17 via azide-alkyne Huisgen cycloaddition (i.e. copper (I) catalyzed variant, 
where organic azides and terminal alkynes are united to afford 1,4-regioisomers of 1,2,3-triazoles as 
single products). 
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Scheme 1. Synthetic scheme for the molecules AST_1–3. 
2.4. FABP4 inhibition evaluation 
FABP4 inhibitory activity was determined with a commercially available screening assay kit, by 
measuring the decreasing in fluorescence of a detection reagent (which is supplied in the kit) when 
displaced by an inhibitor of FABP4. Specifically, the detection reagent exhibits increased 
fluorescence when bound to FABP4. Binding of the detection reagent is monitored by exciting at 
370 nm and measuring the emission at 470 nm. Therefore, any powerful inhibitor of the protein, 
which binds to the same binding pocket, can displace the detection reagent, thereby reducing the 
fluorescence read-out. Inhibition activity data are expressed as IC50 (µM) and results obtained with 
AST_1–3 are reported in Table 4. Arachidonic acid, a known powerful ligand of FABP4, was used 
as a positive control and revealed an IC50 of 3.06 µM. Our set of compounds, AST_1–3, showed 
IC50 values of 5.59, 3.70, and 4.31, respectively. 
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Table 4 
Measured IC50 values for Arachidonic acid and AST_1–3 in FABP4. 
Compounds IC50 (µM) 
Arachidonic acid 3.06 ±0.22 
AST_1 5.59 ±0.79 
AST_2 3.70 ±0.34 
AST_3 4.31 ±0.67 
 
3. Conclusion 
FABP4 provides an attractive therapeutic and diagnostic target for a variety of diseases as 
demonstrated in a variety of animal models [48-51]. FABP4 inhibitors could also be effective for 
the treatment of cancer patients via the inhibition or reduction of early-stage tumors and metastasis. 
Similarly, they show effective as biomarkers for the diagnosis of different types of cancers [52-58]. 
In addition, FABP inhibitors could also be used for the treatment of neurological disorders [59-62]. 
In this study, a 3D-QSAR model for known FABP4 inhibitors was produced and used to study a 
large library of molecules as possible inhibitors of FABP4, by means of scaffold-hopping analysis. 
The efficient predictive capabilities of the QSAR model was also proved through the synthesis of 
three new compounds as FABP4 inhibitors, using the information obtained from the QSAR 
equation. FABP4 binding affinities of the newly designed compounds (AST_1–3) were measured 
by means of an established displacement assay, showing that they are FABP4 inhibitors in the low 
micromolar range (i.e. IC50 values between 3.70 and 5.59 M). Moreover, a large number of 
different molecules were also theorized to be as effective as the three synthesized and can be a 
useful starting point for the design of others FABP4 inhibitors. Our results widely demonstrate that 
simple modifications performed on different sites of the gold standard BMS309403 can retain or 
even improve FABP4 inhibitory activity of the analogs. These findings, of course, should be 
validated experimentally but are considered a reasonable starting point for the researchers in the 
field. Surely, these findings will lead our future research in the field of the development of FABP4 
inhibitors. Considering this transporter as a very promising target, the ultimate goal is to finally 
bring optimized molecules into clinical research phase. 
 
4. Experimental Section 
4.1. Molecular modeling and biological data 
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The 120 structures used to build and evaluate the 3D-QSAR model were chosen among the 
structures previously published [19, 21, 22, 24, 25, 63, 64]. All molecules possess an excellent 
selectivity toward the FABP4 and the range of activities is broad enough to be able to build an 
efficient model. The 2D chemical structures were built by Marvin Sketch, and all structures were 
subjected to molecular mechanics energy minimization using the MMFF94 force field present in the 
same software [65]. Once obtained the 3D structures of all compounds the geometry was also 
optimized at the semi-empirical level of theory using the PM3 Hamiltonian [66], as implemented in 
MOPAC 2016 package [67]. The protonation states of the molecules were calculated assuming a 
pH of 7.0. Forge 10.4.2 (Cresset BioMolecular Discovery Ltd., https://www.cresset-group.com/) 
was used for the building of the 3D-QSAR model. Spark 10.4.0 was used for the scaffold-hopping 
analysis (Cresset BioMolecular Discovery Ltd., https://www.cresset-group.com/). Forge’s 
parameters used for conformation hunt/alignment and to build/validate the QSAR model are 
reported in the Data in Brief related article. 
 
4.2. Chemistry  
All chemicals were purchased from Merk, Sigma Aldrich, and Acros Organics and were reagent 
grade or better. Solvents were purchased from Fisher Scientific, Sigma Aldrich, and VWR. Silica 
gel for column chromatography was purchased from Merck. Samples were dried in a vacuum oven 
(Gallenkamp, rated to ≤250 °C) connected to a vacuum pump (BOC-Edwards.). Pre-coated 
aluminum sheets (silica gel 60 F254, Merck) were used for thin-layer chromatography (TLC) and 
spots were visualized under UV light.
 1
H NMR and 
13
C NMR spectra were recorded on Varian 
UNITY Inova spectrometer using CDCl3 or DMSO-d6 as a solvent and tetramethylsilane (TMS) as 
an internal standard, at 200 or 500 MHz for 
1
H NMR and 125 MHz for 
13
C NMR. 
13
C spectra were 
1
H decoupled and multiplicities were determined by the APT pulse sequence. Chemical shift (δ) 
values are given in ppm. All of the NMR experiments were analyzed using the General NMR 
Analysis Toolbox (GNAT) [68]. Mass spectra were run at King’s College London (UK) on a 
Thermofisher LCQ DECA XP ion trap mass spectrometer or a Waters - Micromass ZQ - Single 
quadrupole mass spectrometer. HPLC analyses were performed on Agilent 1100 series HPLC with 
quadrupole pump, vacuum degasser, variable wavelength detector (set to 254 or 281 nm), using a 
gradient water/acetonitrile as reported in the supporting information. Elemental analyses for C, H, 
N, and S were performed on a Carlo Erba Elemental Analyzer Mod. 1108 apparatus. 
 
4.2.1 General procedure for the synthesis of alcohols 10 
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A solution of benzyl bromide 8 (0.02 mol) in Et2O (50 mL) was dropwise added to a stirred 
suspension of Mg (0.025 mol) over a period of 2 h at room temperature. The mixture was stirred for 
3 additional hours more at room temperature to produce benzyl Grignard 9 and cooled to –40 °C. A 
solution of aldehyde 7 (0.01mol) in Et2O (50 mL) was added over a period of 1 h. The mixture was 
stirred for 2 h at –40 °C, gradually brought to room temperature and stirred for 3 h more. After 
addition of saturated aqueous NH4Cl (10 mL), the mixture was extracted with EtOAc. The 
combined organic extracts were washed with water, brine and dried over Na2SO4. Solvent removal 
under reduced pressure and column chromatography of the residue (silica gel, 93/7, 
cyclohexane/EtOAc) afforded the pure alcohol 10. Yields 92–99%. 
 
4.2.2 General procedure for the synthesis of ketones 11 
A solution of 10 (8.0 mmol) was added to a stirred suspension of pyridinium chlorochromate (12 
mmol) in CH2Cl2 (60 mL). The mixture was stirred at room temperature for nearly 3 h until the 
disappearance of the starting material (monitored by TLC), diluted with diethyl ether (50 mL) and 
filtered through a column of celite. Solvent removal of the filtrate under reduced pressure and 
column chromatography of the residue (silica gel, 95/5, cyclohexane/EtOAc) afforded pure 11. 
Yields 95–99%. 
 
4.2.3 General procedure for the synthesis of -bromoketone 12 
Bromine (3.8 mmol) was added dropwise to a solution of 11 (2.5 mmol) in freshly distilled CHCl3 
(10 mL). The mixture was heated under reflux until conversion was complete (monitored by TLC). 
After cooling, the solvent was evaporated under reduced pressure to provide a residue that was 
purified via column chromatography (silica gel, cyclohexane) to yield pure -bromoketone 12. 
Yields 70–85%. 
 
4.2.4 General procedure for the synthesis of 2-Aminothiobenzamide 14 
Lawesson’s reagent (8.0 mmol) was added to a solution of 13 (14.7 mmol) in THF (75 mL). The 
mixture was stirred under N2 at room temperature for 24h. The solvent was evaporated, and the 
residue partitioned between EtOAc (50 mL), and 1 N HCl (30 mL). Aqueous sat. NaHCO3 was 
added to the aqueous layer until pH= 8–9. This basic solution was extracted with EtOAc (30 mL). 
The combined organic layers were dried (Na2SO4) and filtered. The solvent was evaporated and the 
resulting solid residue was recrystallized from toluene to afford pure 14 as a yellow solid; yield 
72%. 
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4.2.5 General procedure for the synthesis of thiazole 15 
The 2-aminothiobenzamide 14 (1.5 mmol) was added to a solution of -bromoketone 12 (1.0 
mmol) in methanol. The mixture was refluxed overnight. After cooling, the solvent was evaporated 
under reduced pressure to provide a residue that was purified by column chromatography (silica gel, 
99/1, cyclohexane/EtOAc) to yield pure thiazoles 15. 15_1: yield 75%, yellow solid, m.p.: 168–170 
°C. 
1
H NMR (200 MHz, Chloroform-d) δ 6.22 (bs, 2H), 6.58 – 6.88 (m, 2H), 7.04–7.47 (m, 9H), 
7.57 (m, 3H). 
13
C NMR (50 MHz, chloroform-d) δ 113.63, 116.77, 116.82, 127.60, 127.68, 127.92, 
128.16, 128.55, 128.63, 128.87, 129.58, 129.83, 130.59, 145.64, 149.16, 166.96. 15_2: yield 76%, 
yellow solid, m.p.: 178–180 °C. 1H NMR (200 MHz, chloroform-d) δ 6.42–6.85 (m, 2H), 7.17–7.54 
(m, 9H), 7.54–7.89 (m, 6H), 7.99–8.22 (m, 1H), 8.68 (s, 1H). 13C NMR (50 MHz, chloroform-d) δ 
110.92, 115.13, 126.18, 126.27, 126.89, 127.69, 127.79, 128.19, 128.34, 128.78, 129.26, 129.72, 
130.87, 131.32, 131.94, 132.56, 132.86, 133.37, 147.61, 148.92. 
15_3: yield 81%, yellow solid, m.p.: 172–173 °C. 
 
4.2.6 General procedure for the synthesis of 3-butynoic acid 17 
A solution of 21 g (0.3 mol) of 3-butyn-1-ol 16 in acetone (300 mL) was added dropwise to a stirred 
solution of chromium trioxide (60 g, 0.6mol) in 750 mL of 10 N H2S04 at 0 °C. The reaction 
mixture was allowed to warm to room temperature and the stirring was continued for 1.5 h. The 
liquid was decanted into a mixture of EtOAc and H2O. The aqueous layer was extracted five times 
with EtOAc. The extracts were combined, washed twice with saturated NaCl solution, dried 
(Na2SO4) and evaporated. The resulting solid residue was recrystallized from hexane to afford pure 
17 as a white solid, yield 93%. 
 
4.2.7 General procedure for the synthesis of final compounds AST_1–3 
The suitable thiazole 15 (0.54 mmol) was dissolved in THF (2 mL) in a 25 mL round-bottomed 
flask and cooled to 0 °C in an ice-bath. t-BuONO (0.81 mmol) and TMSN3 (0.65 mmol) were 
sequentially added to this mixture under stirring. The resulting solution was reacted at room 
temperature for 2 h. 3-Butinoic acid 17 (0.54 mmol), an aq. solution (0.2 mL) of CuSO4 (0.027 
mmol), sodium ascorbate (0.108 mmol) were then added and the reaction was stirred overnight at 
room temperature. The crude mixture was concentrated under vacuum and the product was then 
precipitated by addition of water to give the final compounds AST_1–3. AST_1: white solid, m.p.: 
238–240 °C. 1H NMR (500 MHz, DMSO-d6) δ 3.62 (s, 2H), 7.11–7.47 (m, 10H), 7.56 (d, J = 7.5 
Hz, 1H), 7.73 (m, 2H), 8.08–8.47 (m, 2H). Anal. Calcd. for C25H18N4O2S: C, 68.48; H, 4.14; N, 
12.78; S, 7.31; found C, 68.11; H, 4.10; N, 12.89; S, 7.22. AST_2: white solid, m.p.: 241–243 °C. 
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1
H NMR (500 MHz, DMSO-d6) δ 3.57 (s, 2H), 7.28 (d, J = 7.9 Hz, 2H), 7.36 (m, 3H), 7.43–7.52 
(m, 2H), 7.55 (d, J = 7.9 Hz, 1H), 7.64–7.74 (m, 1H), 7.74–7.83 (m, 3H), 7.83–7.91 (m, 1H), 7.95 
(s, 1H), 8.26 (d, J = 6.7 Hz, 2H). Anal. Calcd. for C29H20N4O2S: C, 71.29; H, 4.13; N, 11.47; S, 
6.56; found C, 71.54; H, 4.18; N, 11.38; S, 6.33. AST_3: white solid, m.p.: 241–242 °C. 1H NMR 
(500 MHz, chloroform-d) δ 3.98 (s, 2H), 7.13 (t, J = 7.8 Hz, 1H), 7.17–7.24 (m, 2H), 7.25–7.37 (m, 
5H), 7.44 (t, J = 1.9 Hz, 1H), 7.50 (dd, J = 7.8, 1.3 Hz, 1H), 7.59 (td, J = 7.7, 1.5 Hz, 1H), 7.66 (td, 
J = 7.7, 1.5 Hz, 1H), 7.89 (s, 1H), 8.15 (dd, J = 7.7, 1.5 Hz, 1H). 
13
C NMR (50 MHz, chloroform-d) 
δ 29.68, 126.94, 127.93, 128.11, 128.72, 128.86, 128.96, 129.35, 129.53, 130.35, 130.70, 134.07, 
136.05, 160.12. Anal. Calcd. for C25H17ClN4O2S: C, 63.49; H, 3.62; N, 11.85; S, 6.78; found C, 
63.34; H, 3.61; N, 11.92; S, 6.72. 
 
4.3. FABP inhibitory activity assays 
To analyze the inhibitory activity of FABP4 ligands, a displacement assay was utilized as described 
by the Cayman’s instruction, FABP4 Inhibitor/Ligand Screening Assay Kit, Item 10010231. The 
samples of compounds AST_1–3 for activity determination were prepared as a stock solution (1 
mM) in DMSO. On the day of activity assay, the compounds were all diluted in phosphate buffer 
solution (PBS, pH 7.4) to different concentrations (50, 25, 12.5, 6.25, 3.12, 1.56 and 0.15 M). 
Appropriate concentrations of DMSO in PBS was used as control. The detection reagent (FABP 
Assay Detection Reagent, Item 10010376) was used as provided by the Cayman’s kit. The diluted 
Detection Reagent probe was mixed with FABP4 protein present in the kit and incubated for 10 min 
at room temperature. Compounds were then added and equilibrated for another 10 min. Lastly, the 
fluorescence signal was recorded at 470 nm (i.e. emission, with the excitation fixed at 370 nm) with 
a CytoFluor® Series 4000 Fluorescence Multi-Well Plate Reader. The plotted displacement curves 
for Arachidonic acid (positive control) and AST_1–3 are reported in the supporting information. 
 
Appendix A. Supplementary data 
Supplementary data related to this article can be found at https://doi.org/ 
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